Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Podzamczer, D.    Gudiol, F.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Intermittent Trimethoprim-Sulfamethoxazole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV

Daniel Podzamczer; Albert Salazar; Josep Jimenez; Ezequiel Consiglio; Miguel Santin; Aurora Casanova; Gabriel Rufi; and Francisco Gudiol

15 May 1995 | Volume 122 Issue 10 | Pages 755-761

Objective: To evaluate the efficacy and safety of two oral, intermittent drug regimens for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV infection.

Design: Nonblinded randomized study: Patients received either 1) trimethoprim-sulfamethoxazole [160 mg-800 mg orally twice a day on a thrice weekly regimen] or 2) 100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly.

Setting: University teaching hospital in Barcelona.

Patients: 230 patients infected with HIV who had CD4 cell counts of less than 200 x 10⁶/L and who had not previously had P. carinii pneumonia or toxoplasmosis.

Measurements: Clinical and biological evaluations; adverse reactions; and end points of P. carinii pneumonia, toxoplasmosis, and death.

Results: After a median follow-up of 430 days, 6 (6.3%) of 96 evaluable patients receiving dapsone-pyrimethamine and 0 of 104 evaluable patients receiving trimethoprim-sulfamethoxazole developed P. carinii pneumonia (P < 0.0001). The cumulative rates of P. carinii pneumonia at 12 and 24 months were 0% and 0% for patients receiving trimethoprim-sulfamethoxazole and 4% and 11% for patients receiving dapsone-pyrimethamine (Mantel-Cox, P = 0.014). However, only one episode of P. carinii pneumonia developed while patients were taking these drugs. No differences were observed for toxoplasmosis (one episode in the trimethoprim-sulfamethoxazole arm and two in the dapsone-pyrimethamine arm), with cumulative rates at 12 and 24 months of 0% and 4% for the trimethoprim-sulfamethoxazole arm and 2% and 7% for the dapsone-pyrimethamine arm (P = 0.65). Similar mortality rates were observed during follow-up (P = 0.85). Nineteen patients (9.5%) discontinued therapy with the drugs because of adverse effects: Ten were in the trimethoprim-sulfamethoxazole arm and 9 were in the dapsone-pyrimethamine arm (P = 0.95).

Conclusions: Thrice-weekly trimethoprim-sulfamethoxazole is an effective and well-tolerated regimen for the simultaneous primary prophylaxis of P. carinii pneumonia and toxoplasmosis in patients infected with HIV. Twice-weekly dapsone-pyrimethamine appears to be a safe and effective alternative.

Author and Article Information

From Ciutat Sanitaria de Bellvitge, University of Barcelona, Barcelona, Spain.
Requests for Reprints: Daniel Podzamczer, MD, Infectious Disease Service, Ciutat Sanitaria de Bellvitge, c/Feixa Llarga s/n, L'Hospitalet, 08907 Barcelona, Spain.
Grant Support: In part by grant FISS 91/0469 from the Fondo de Investigacion de la Seguridad Social.

This article has been cited by other articles:

				M. Rodriguez and J. A. Fishman Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients Clin. Microbiol. Rev., October 1, 2004; 17(4): 770 - 782. [Abstract] [Full Text] [PDF]

				P. b. H. Masur, J. E. Kaplan, and K. K. Holmes Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America Ann Intern Med, September 3, 2002; 137(5_Part_2): 435 - 478. [Abstract] [Full Text] [PDF]

				A. L. Baggish and D. R. Hill Antiparasitic Agent Atovaquone Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1163 - 1173. [Full Text] [PDF]

				R. G. Nelson and A. Rosowsky Dicyclic and Tricyclic Diaminopyrimidine Derivatives as Potent Inhibitors of Cryptosporidium parvum Dihydrofolate Reductase: Structure-Activity and Structure-Selectivity Correlations Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3293 - 3303. [Abstract] [Full Text] [PDF]

				J. C. L. B. de Quiros, J. M. Miro, J. M. Pena, D. Podzamczer, J. C. Alberdi, E. Martinez, J. Cosin, X. Claramonte, J. Gonzalez, P. Domingo, et al. A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection N. Engl. J. Med., January 18, 2001; 344(3): 159 - 167. [Abstract] [Full Text] [PDF]

				P.-M. Girard Discontinuing Pneumocystis carinii Prophylaxis N. Engl. J. Med., January 18, 2001; 344(3): 222 - 223. [Full Text] [PDF]

				B. D. Purdy Management and Prevention of Opportunistic Infections in the HIV-Infected Patient Journal of Pharmacy Practice, December 1, 2000; 13(6): 475 - 498. [Abstract] [PDF]

				J. A. Kovacs and H. Masur Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., May 11, 2000; 342(19): 1416 - 1429. [Full Text] [PDF]

				USPHS/IDSA Prevention of Opportunistic Infections 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus Ann Intern Med, December 7, 1999; 131(11): 873 - 908. [Full Text] [PDF]

				J. A. Fishman Prevention of Infection Due to Pneumocystis carinii Antimicrob. Agents Chemother., May 1, 1998; 42(5): 995 - 1004. [Full Text]

				Two Regimens for Preventing PCP and Toxoplasmosis AIDS Clinical Care, July 1, 1995; 1995(701): 5 - 5. [Full Text]